Biocon Biologics Re-registers UK Entity as a Public Limited Company

Biocon Limited informed stock exchanges that its step-down subsidiary, Biocon Biologics UK Limited, has been re-registered as a Public Limited Company. The entity will now be known as Biocon Biologics UK PLC, effective October 29, 2025.

Details of the Announcement

The information was shared through an official filing dated October 30, 2025, with the BSE and NSE. The company stated that the re-registration and name change were completed following confirmation from its material subsidiary, Biocon Biologics Limited (BBL).

Subsidiary Relationship

Biocon Limited is the parent company, while Biocon Biologics Limited is one of its material subsidiaries. The UK-based entity, Biocon Biologics UK PLC, operates as a subsidiary under Biocon Biologics Limited. This makes it a step-down subsidiary in the overall corporate structure.

Timeline of Events

Biocon had earlier notified exchanges on October 23, 2025, about the planned changes in the status and name of the UK subsidiary. The process was finalised on October 29, 2025, after regulatory procedures were completed in the United Kingdom.

Filing Reference 

The update was released recently and signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer of Biocon Limited. The filing mentioned that the revised details are available on the company’s website.

Biocon Share Price Performance 

As of October 31, 2025, 10:13 AM, Biocon share price was trading at ₹375.10, a 0.40% down from the previous closing price.

Read More: Civica to Manage US Insulin Distribution and Marketing for Biocon Biologics!

Conclusion

With this re-registration, Biocon Biologics UK PLC will now function as a Public Limited Company under UK law. The change is limited to the entity’s legal structure and name, while its association within the Biocon Biologics group remains unchanged.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.